talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
Published 8 months ago • 83 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
2:45
arrow: psma-targeted radioligand therapy plus enzalutamide in mcrpc
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
6:46
what is provenge? learn about immunotherapy for prostate cancer
-
15:40
rectal bleeding and proctitis following prostate cancer treatment
-
5:15
rucaparib and olaparib: two new treatments approved for advanced prostate cancer | pcri
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
6:49
ramp: phase ib study of rucaparib & enzalutamide in mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
2:26
caspar: the addition of rucaparib to enzalutamide for the treatment of mcrpc
-
6:35
talazoparib plus enzalutamide: talapro-2 results and subset analyses
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
5:52
talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
2:24
real-world psa responses to apalutamide or enzalutamide in mcspc
-
11:19
drs. fizazi, wallis on updated data from talapro-2